Cargando…
Factors of interrupting chemotherapy in patients with Advanced Non-Small-Cell Lung Cancer
BACKGROUND: Little is known about prognosis of metastatic patients after receiving a first-line treatment and failure. Our group already showed in pre-treated patients enrolled in phase I clinical trials that a performance status (PS) > 2 and an LDH > 600 UI/L were independent prognostic facto...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2904794/ https://www.ncbi.nlm.nih.gov/pubmed/20537187 http://dx.doi.org/10.1186/1756-0500-3-164 |
_version_ | 1782183913887629312 |
---|---|
author | Belbaraka, Rhizlane Trédan, Olivier Ray-Coquard, Isabelle Chvetzoff, Giselle Bajard, Agathe Pérol, David Ismaili, Nabil Ismaili, Mohammed Errihani, Hassan Bachelot, Thomas Rebattu, Paul |
author_facet | Belbaraka, Rhizlane Trédan, Olivier Ray-Coquard, Isabelle Chvetzoff, Giselle Bajard, Agathe Pérol, David Ismaili, Nabil Ismaili, Mohammed Errihani, Hassan Bachelot, Thomas Rebattu, Paul |
author_sort | Belbaraka, Rhizlane |
collection | PubMed |
description | BACKGROUND: Little is known about prognosis of metastatic patients after receiving a first-line treatment and failure. Our group already showed in pre-treated patients enrolled in phase I clinical trials that a performance status (PS) > 2 and an LDH > 600 UI/L were independent prognostic factors. In this prospective study, which included 45 patients, we identified clinical and biological variables as outcome predictors in metastatic Non-Small Cell lung cancer after first line chemotherapy were identified. FINDINGS: Forty-five patients that were previously treated for metastatic disease from 12/2000 to 11/2005 in the comprehensive cancer centre (Centre Léon Bérard). Clinical assessment and blood parameters were recorded and considered. Patient prognostic factors for overall survival (OS) with a 0.05-significance level in univariate analysis were entered in a multivariate Cox model for further analysis. Patients' median age was 58.5 years (range: 37 - 76). Sixty two percent of the patients were PS = 0 or 1. After inclusion, nine patients received second-line (22.5%), and two received third-line chemotherapy (5%). Univariate analysis showed that the factors associated with reduced OS were: PS > 2, weight loss >10%, more than one line of chemotherapy treatment and abnormal blood parameters (hemoglobin (Hb), platelet and neutrophils counts). Multiple regression analysis confirmed that PS > 2 and abnormal hemoglobin were independent predictors for low overall survival. According to the presence of none (33%), 1 (37%) and 2 (30%) prognostic factors, median OS were 12, 5 and 2 months respectively. CONCLUSION: From this prospective study, both PS and anemia were found as independent determinants of survival, we found that both PS and anemia were independent determinants of survival. The combination of poor PS and anemia is an effective strategy to predict survival in the case of patients with metastatic NSCLC receiving further treatment after the first line. |
format | Text |
id | pubmed-2904794 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-29047942010-07-16 Factors of interrupting chemotherapy in patients with Advanced Non-Small-Cell Lung Cancer Belbaraka, Rhizlane Trédan, Olivier Ray-Coquard, Isabelle Chvetzoff, Giselle Bajard, Agathe Pérol, David Ismaili, Nabil Ismaili, Mohammed Errihani, Hassan Bachelot, Thomas Rebattu, Paul BMC Res Notes Short Report BACKGROUND: Little is known about prognosis of metastatic patients after receiving a first-line treatment and failure. Our group already showed in pre-treated patients enrolled in phase I clinical trials that a performance status (PS) > 2 and an LDH > 600 UI/L were independent prognostic factors. In this prospective study, which included 45 patients, we identified clinical and biological variables as outcome predictors in metastatic Non-Small Cell lung cancer after first line chemotherapy were identified. FINDINGS: Forty-five patients that were previously treated for metastatic disease from 12/2000 to 11/2005 in the comprehensive cancer centre (Centre Léon Bérard). Clinical assessment and blood parameters were recorded and considered. Patient prognostic factors for overall survival (OS) with a 0.05-significance level in univariate analysis were entered in a multivariate Cox model for further analysis. Patients' median age was 58.5 years (range: 37 - 76). Sixty two percent of the patients were PS = 0 or 1. After inclusion, nine patients received second-line (22.5%), and two received third-line chemotherapy (5%). Univariate analysis showed that the factors associated with reduced OS were: PS > 2, weight loss >10%, more than one line of chemotherapy treatment and abnormal blood parameters (hemoglobin (Hb), platelet and neutrophils counts). Multiple regression analysis confirmed that PS > 2 and abnormal hemoglobin were independent predictors for low overall survival. According to the presence of none (33%), 1 (37%) and 2 (30%) prognostic factors, median OS were 12, 5 and 2 months respectively. CONCLUSION: From this prospective study, both PS and anemia were found as independent determinants of survival, we found that both PS and anemia were independent determinants of survival. The combination of poor PS and anemia is an effective strategy to predict survival in the case of patients with metastatic NSCLC receiving further treatment after the first line. BioMed Central 2010-06-10 /pmc/articles/PMC2904794/ /pubmed/20537187 http://dx.doi.org/10.1186/1756-0500-3-164 Text en Copyright ©2010 Belbaraka et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Short Report Belbaraka, Rhizlane Trédan, Olivier Ray-Coquard, Isabelle Chvetzoff, Giselle Bajard, Agathe Pérol, David Ismaili, Nabil Ismaili, Mohammed Errihani, Hassan Bachelot, Thomas Rebattu, Paul Factors of interrupting chemotherapy in patients with Advanced Non-Small-Cell Lung Cancer |
title | Factors of interrupting chemotherapy in patients with Advanced Non-Small-Cell Lung Cancer |
title_full | Factors of interrupting chemotherapy in patients with Advanced Non-Small-Cell Lung Cancer |
title_fullStr | Factors of interrupting chemotherapy in patients with Advanced Non-Small-Cell Lung Cancer |
title_full_unstemmed | Factors of interrupting chemotherapy in patients with Advanced Non-Small-Cell Lung Cancer |
title_short | Factors of interrupting chemotherapy in patients with Advanced Non-Small-Cell Lung Cancer |
title_sort | factors of interrupting chemotherapy in patients with advanced non-small-cell lung cancer |
topic | Short Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2904794/ https://www.ncbi.nlm.nih.gov/pubmed/20537187 http://dx.doi.org/10.1186/1756-0500-3-164 |
work_keys_str_mv | AT belbarakarhizlane factorsofinterruptingchemotherapyinpatientswithadvancednonsmallcelllungcancer AT tredanolivier factorsofinterruptingchemotherapyinpatientswithadvancednonsmallcelllungcancer AT raycoquardisabelle factorsofinterruptingchemotherapyinpatientswithadvancednonsmallcelllungcancer AT chvetzoffgiselle factorsofinterruptingchemotherapyinpatientswithadvancednonsmallcelllungcancer AT bajardagathe factorsofinterruptingchemotherapyinpatientswithadvancednonsmallcelllungcancer AT peroldavid factorsofinterruptingchemotherapyinpatientswithadvancednonsmallcelllungcancer AT ismailinabil factorsofinterruptingchemotherapyinpatientswithadvancednonsmallcelllungcancer AT ismailimohammed factorsofinterruptingchemotherapyinpatientswithadvancednonsmallcelllungcancer AT errihanihassan factorsofinterruptingchemotherapyinpatientswithadvancednonsmallcelllungcancer AT bachelotthomas factorsofinterruptingchemotherapyinpatientswithadvancednonsmallcelllungcancer AT rebattupaul factorsofinterruptingchemotherapyinpatientswithadvancednonsmallcelllungcancer |